Zymeworks receives U.S. FDA Fast Track Designation for ZW191, an FRα-targeting ADC

RemeGen’s dual-antibody ADC RC288 for the treatment of advanced malignant solid tumors has been officially...

Invenra Highlights Exelixis’ Announcement: Initiation of Phase 1 Clinical Trial Evaluating XB010 in Patients with...

Daiichi Sankyo and MSD expand collaboration on ADC development

Exelixis drops tissue factor-targeting ADC after deciding it’s no match for Tivdak

Salubris Biotherapeutics Announces European Medicines Agency Approval to Initiate a Phase 1 Clinical Trial of...